Jump to content

Draft:Yunlong Cao

From Wikipedia, the free encyclopedia
  • Comment: The sources given are primary sources (works made by the subject), and don't establish notability on Wikipedia. If you are connected to the subject, please thoroughly read WP:COI. LR.127 (talk) 22:52, 12 August 2024 (UTC)

Yunlong Cao (Chinese:曹云龙; pinyin: Cáo Yúnlóng) is a Chinese immunologist and Assistant Professor in Biomedical Pioneering Innovation Center (BIOPIC) and Peking-Tsinghua Center for Life Sciences, at Peking University.[1][2]He is also a principal investigator at Beijing Changping Laboratory.[3]

Education and career

[edit]

Cao completed his undergraduate studies in Physics at Zhejiang University, graduating in 2014. He then went on to earn a Ph.D. in Chemistry from Harvard University in 2019 while under the research direction of Prof. Xiaoliang Sunney Xie.[1] Following his Ph.D, he came back to China and became a Research Associate at Biomedical Pioneering Innovation Center (BIOPIC), Peking University. In 2023, Cao started an independent laboratory as assistant professor.[1][2][3]

Research

[edit]

Cao's lab investigates humoral immunity and antibodies at single-cell and molecular level, with particular focuses on antibody response, immune escape and immune imprinting in infectious diseases and the development of broad-spectrum antibody therapeutics and vaccines against highly mutating viruses such as HIV, influenza virus and SARS-CoV-2.[1][4][5][6][7][8]

During the COVID-19 pandemic, Cao's laboratory made key contributions to the understanding of SARS-CoV-2 neutralizing antibodies, humoral immunity of SARS-CoV-2 vaccination and infection, and antibody escape of SARS-CoV-2 variants.[4][5][6][7][8] His lab developed a high-throughput deep mutational scanning (DMS) technology and a platform for high-throughput antibody selection and characterization.[7] Using this platform, they characterized the humoral immune escape by SARS-CoV-2 Omicron and its emerging sublineages,[6][7][9][10][11] revealing the molecular mechanism behind immune imprinting and convergent evolution of Omicron.[5][6] His team also pioneered a computational model to rationally predict the direction of SARS-CoV-2 RBD evolution.[5] Using this model, Cao's lab was able to predict several of the key mutations and mutants that have later emerged, laying a key foundation for updating vaccine components and adjusting pandemic control policies. Based on viral evolution prediction, his lab proposed strategies for screening broadly neutralizing antibodies against SARS-CoV-2 and identified SARS-CoV-2 bNAbs such as SA55 and BD55-1205.[12]

Academic honors and service

[edit]
  • 2023 The Coalition for Epidemic Preparedness Innovations (CEPI) Scientific Advisory Committee[13]
  • 2023 WHO Technical Advisory Group on COVID-19 Vaccine Composition
  • 2022 Beijing Outstanding Young Talent Award (ZhongGuanCun Award)[14]
  • 2022 China's top 10 scientific advances[15]
  • 2022 China's top 10 advances in life sciences[16]
  • 2022 Nature's "Ten people who helped shape science in 2022" (Nature's 10)[17]
  • 2021 "35 Innovators Under 35" (China) by MIT Technology Review[18]
[edit]

References

[edit]
  1. ^ a b c d "Yunlong Cao, PhD". BIOPIC, PKU. Retrieved 10 August 2024.
  2. ^ a b "Yunlong Cao, PhD". Peking-Tsinghua Center for Life Sciences. Retrieved 10 August 2024.
  3. ^ a b "Yunlong Cao". Changping Laboratory. Retrieved 10 August 2024.
  4. ^ a b Ayijiang Yisimayi, Weiliang Song, Jing Wang, Fanchong Jian, Yuanling Yu, Xiaosu Chen, Yanli Xu, Sijie Yang, Xiao Niu, Tianhe Xiao, Jing Wang, Lijuan Zhao, Haiyan Sun, Ran An, Na Zhang, Yao Wang, Peng Wang, Lingling Yu, Zhe Lv, Qingqing Gu, Fei Shao, Ronghua Jin, Zhongyang Shen, Xiaoliang Sunney Xie, Youchun Wang, Yunlong Cao (2024). "Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting". Nature. 625 (7993): 148–156. Bibcode:2024Natur.625..148Y. doi:10.1038/s41586-023-06753-7. PMC 10764275. PMID 37993710.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ a b c d Yunlong Cao, Fanchong Jian, Jing Wang, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Jing Wang, Ran An, Xiaosu Chen, Na Zhang, Yao Wang, Peng Wang, Lijuan Zhao, Haiyan Sun, Lingling Yu, Sijie Yang, Xiao Niu, Tianhe Xiao, Qingqing Gu, Fei Shao, Xiaohua Hao, Yanli Xu, Ronghua Jin, Zhongyang Shen, Youchun Wang, Xiaoliang Sunney Xie (2023). "Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution". Nature. 614 (7948): 521–529. Bibcode:2023Natur.614..521C. doi:10.1038/s41586-022-05644-7. PMC 9931576. PMID 36535326.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ a b c d Yunlong Cao, Ayijiang Yisimayi, Fanchong Jian, Weiliang Song, Tianhe Xiao, Lei Wang, Shuo Du, Jing Wang, Qianqian Li, Xiaosu Chen, Yuanling Yu, Peng Wang, Zhiying Zhang, Pulan Liu, Ran An, Xiaohua Hao, Yao Wang, Jing Wang, Rui Feng, Haiyan Sun, Lijuan Zhao, Wen Zhang, Dong Zhao, Jiang Zheng, Lingling Yu, Can Li, Na Zhang, Rui Wang, Xiao Niu, Sijie Yang, Xuetao Song, Yangyang Chai, Ye Hu, Yansong Shi, Linlin Zheng, Zhiqiang Li, Qingqing Gu, Fei Shao, Weijin Huang, Ronghua Jin, Zhongyang Shen, Youchun Wang, Xiangxi Wang, Junyu Xiao, Xiaoliang Sunney Xie (2022). "BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection". Nature. 608 (7923): 593–602. Bibcode:2022Natur.608..593C. doi:10.1038/s41586-022-04980-y. PMC 9385493. PMID 35714668.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ a b c d Yunlong Cao, Jing Wang, Fanchong Jian, Tianhe Xiao, Weiliang Song, Ayijiang Yisimayi, Weijin Huang, Qianqian Li, Peng Wang, Ran An, Jing Wang, Yao Wang, Xiao Niu, Sijie Yang, Hui Liang, Haiyan Sun, Tao Li, Yuanling Yu, Qianqian Cui, Shuo Liu, Xiaodong Yang, Shuo Du, Zhiying Zhang, Xiaohua Hao, Fei Shao, Ronghua Jin, Xiangxi Wang, Junyu Xiao, Youchun Wang, Xiaoliang Sunney Xie (2022). "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies". Nature. 602 (7898): 657–663. Bibcode:2022Natur.602..657C. doi:10.1038/s41586-021-04385-3. PMC 8866119. PMID 35016194.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ a b Yunlong Cao, Bin Su, Xianghua Guo, Wenjie Sun, Yongqiang Deng, Linlin Bao, Qinyu Zhu, Xu Zhang, Yinghui Zheng, Chenyang Geng, Xiaoran Chai, Runsheng He, Xiaofeng Li, Qi Lv, Hua Zhu, Wei Deng, Yanfeng Xu, Yanjun Wang, Luxin Qiao, Yafang Tan, Liyang Song, Guopeng Wang, Xiaoxia Du, Ning Gao, Jiangning Liu, Junyu Xiao, Xiao-Dong Su, Zongmin Du, Yingmei Feng, Chuan Qin, Chengfeng Qin, Ronghua Jin, X Sunney Xie (2020). "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells". Cell. 182 (1): 73–84.e16. doi:10.1016/j.cell.2020.05.025. PMC 7231725. PMID 32425270.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Can Yue, Weiliang Song, Lei Wang, Fanchong Jian, Xiaosu Chen, Fei Gao, Zhongyang Shen, Youchun Wang, Xiangxi Wang, Yunlong Cao (2023). "ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5". The Lancet Infectious Diseases. 23 (3): 278–280. doi:10.1016/S1473-3099(23)00010-5. PMC 9897732. PMID 36746173.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ Cao Yunlong, Song Weiliang, Wang Lei, Liu Pan, Yue Can, Jian Fanchong, Yu Yuanling, Yisimayi Ayijiang, Wang Peng, Wang Yao, Zhu Qianhui, Deng Jie, Fu Wangjun, Yu Lingling, Zhang Na, Wang Jing, Xiao Tianhe, An Ran, Wang Jing, Liu Lu, Yang Sijie, Niu Xiao, Gu Qingqing, Shao Fei, Hao Xiaohua, Meng Bo , Gupta Ravindra Kumar, Jin Ronghua, Wang Youchun, Xie Xiaoliang Sunney, Wang Xiangxi (2022). "Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75". Cell Host & Microbe. 30 (11): 1527–1539.e5. doi:10.1016/j.chom.2022.09.018. PMC 9531665. PMID 36270286.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Sijie Yang, Yuanling Yu, Yanli Xu, Fanchong Jian, Weiliang Song, Ayijiang Yisimayi, Peng Wang, Jing Wang, Jingyi Liu, Lingling Yu, Xiao Niu, Jing Wang, Yao Wang, Fei Shao, Ronghua Jin, Youchun Wang, Yunlong Cao (2024). "Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure". The Lancet Infectious Diseases. 24 (2): e70–e72. doi:10.1016/S1473-3099(23)00744-2. PMID 38109919.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ Yunlong Cao, Fanchong Jian, Zhiying Zhang, Ayijiang Yisimayi, Xiaohua Hao, Linlin Bao, Fei Yuan, Yuanling Yu, Shuo Du, Jing Wang, Tianhe Xiao, Weiliang Song, Ying Zhang, Pulan Liu, Ran An, Peng Wang, Yao Wang, Sijie Yang, Xiao Niu, Yuhang Zhang, Qingqing Gu, Fei Shao, Yaling Hu, Weidong Yin, Aihua Zheng, Youchun Wang, Chuan Qin, Ronghua Jin, Junyu Xiao, Xiaoliang Sunney Xie (2022). "Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents". Cell Reports. 41 (12): 111845. doi:10.1016/j.celrep.2022.111845. PMC 9712074. PMID 36493787.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ^ "SAC Members". CEPI Scientific Advisory Committee. Retrieved 10 August 2024.
  14. ^ "北京市科技进步奖" (PDF). 2022 年北京市科学技术奖授奖清单. Retrieved 10 August 2024.
  15. ^ "China's Top 10 Science Advances in 2022". Bulletin of the Chinese Academy of Sciences. Retrieved 10 August 2024.
  16. ^ "Research by CPL Leading Scientists among China's top 10 advances in life sciences in 2022". Changping Laboratory. Retrieved 10 August 2024.
  17. ^ "2022 Nature's 10". Nature. Retrieved 10 August 2024.
  18. ^ "《麻省理工科技评论》"35岁以下科技创新35人" 中国". MIT Innovators Under 35. Retrieved 10 August 2024.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Yunlong_Cao&oldid=1240159199"